chemotherapy-induced peripheral neuropathy
Conditions
Interventions
Control group:Conventional care
Intervention group:Multimodal exercise intervention and Conventional care
Sponsors
Guangdong Provincial Hospital of Chinese Medicine (Guangdong Provincial Academic of Chinese Medicine Science; Second Clinical Medical College, Guangzhou University of Traditional Chinese Medicine)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Histopathologically confirmed colorectal cancer. 2. Aged >= 18 years and <= 70 years. 3. Currently receiving palliative or adjuvant chemotherapy with an oxaliplatin-containing XELOX/CAPOX regimen (3-week cycle). 4. Presence of grade 1–2 chronic CIPN (chemotherapy-induced peripheral neuropathy) symptoms at baseline assessment (CTCAE v5.0), which persist throughout the interval between the most recent chemotherapy cycles. 5. The attending physician confirmed that the chemotherapy regimen is expected to remain unchanged for the next 9 weeks, and at least 3 complete chemotherapy cycles still need to be completed; 6. ECOG performance status score <= 2.
Exclusion criteria
Exclusion criteria: 1. Accompanied by other neurological disorders that may cause peripheral neuropathy, such as diabetic peripheral neuropathy, Parkinson's disease, myasthenia gravis, etc. 2. Complicated by severe organ dysfunction, uncontrolled cardiopulmonary disease, or hypertension, and deemed unable to tolerate exercise by the attending physician. 3. Presence of motor dysfunction or musculoskeletal disorders (including history of trauma) that impair balance or ambulatory function, such as severe osteoarthritis or unhealed fractures. 4. Presence of uncontrolled symptomatic brain metastases, unstable bone metastases, or a judgment by the attending physician that the patient is unfit for exercise because of widespread tumor metastases. 5. Presence of any condition that impairs communication and cognitive function, including but not limited to aphasia, severe hearing or visual impairment, dementia, and psychiatric disorders. 6. Concurrent enrollment in other interventional clinical research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Enrollment Rate;Intervention Completion Rate;Dropout Rate and Reasons;Safety of the Intervention; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chemotherapy?induced peripheral neuropath;Physical activity;Balance assessment;Exercise self-efficacy;Quality of life;Perceived exercise benefits and barriers; | — |
Countries
China
Contacts
Public ContactWang Danni
Guangdong Provincial Hospital of Chinese Medicine (Guangdong Provincial Academic of Chinese Medicine Science; Second Clinical Medical College, Guangzhou University of Traditional Chinese Medicine)
Outcome results
None listed